...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Response- clear as mud imo

"My two cents, I don't think they could really tell us anything if they were negotiating anything important (which allows management to hide behind that somewhat)."

Agree 100% , believe there in a BO as this statement at the bottom is just too weak - 

 1) You would think with Don's 20 years at the helm he would realize much of this below?

2) Add in the 10-20 millions of dollars to explore pretty much these same insights/avenues with Eversana/Rvx & this below seems even harder to believe?

3) Now add in Cencora , one of the largest companies in the world to this regard which Don has been chatting for 3 months or so he tells us & they haven't figured the below  out yet? 

Now you almost have to believe there in a BO or its all BS imo.Point is & why i believe we should be seeing something soon, as in no later than mid Dec MAX! 

"the initial focus of Cencora’s work will be in evaluating regulatory and market access to provide insights into potential barriers and opportunities for ZEN-3694's introduction'

Share
New Message
Please login to post a reply